ChromaDex (NASDAQ:CDXC) Rating Lowered to “Buy” at StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.

CDXC has been the topic of several other research reports. Roth Mkm lifted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 4th.

ChromaDex Price Performance

ChromaDex stock opened at $5.43 on Wednesday. ChromaDex has a fifty-two week low of $1.36 and a fifty-two week high of $7.97. The firm has a market capitalization of $414.76 million, a PE ratio of 543.54 and a beta of 2.21. The company’s 50-day moving average is $6.40 and its 200-day moving average is $4.40.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the prior year, the business earned ($0.01) EPS. As a group, analysts expect that ChromaDex will post 0.04 EPS for the current year.

Insiders Place Their Bets

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. USA Financial Formulas purchased a new stake in ChromaDex during the 4th quarter worth about $25,000. The Manufacturers Life Insurance Company purchased a new position in shares of ChromaDex during the second quarter worth about $31,000. Merriman Wealth Management LLC purchased a new stake in ChromaDex in the second quarter valued at approximately $32,000. FMR LLC bought a new position in shares of ChromaDex in the 3rd quarter worth $55,000. Finally, Marshall Wace LLP bought a new stake in shares of ChromaDex during the 2nd quarter worth $56,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.